PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise for recurrent ovarian cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
Disease control OngoingThis phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Ovarian cancer drug trial aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC